Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma

Inclusion Criteria: * AFP-expressing HCC and serum AFP \>100 ng/mL. * Measurable disease as defined by: at least 1 liver lesion that can be accurately and serially measured in at least 1 dimension and for which the longest diameter is ≥ 20 mm. * Molecular HLA class I typing confirms participant carries at least one HLA-A02 allele * Child-Pugh score of A or B * Life expectancy \> 4 months * Age at time of enrollment is ≥18 years of age. * KPS ≥70% * Adequate organ function as defined below: * A pretreatment measured creatinine clearance (absolute value) of ≥50 ml/minute. * Patients must have a serum direct bilirubin ≤2 x ULN, ALT and AST ≤5 times the institutional upper limits of normal. * Ejection Fraction measured by echocardiogram or MUGA \>45% (evaluation done within 6 weeks of screening does not need to be repeated) * DLCO or FEV1 \>45% predicted * Absolute neutrophil count (ANC) ≥ 1500/mm3 (10\^9/L) * Platelet count ≥ 50,000/mm3 (10\^9/L) * Negative serum pregnancy test for women with childbearing potential * Informed Consent/Assent: All subjects must have the ability to understand and the willingness to sign a written informed consent. Exclusion criteria: * Patients with decompensated cirrhosis: Child-Pugh Score C * Patients with an organ transplantation history * Patients with tumor infiltration in the portal vein, hepatic veins or inferior vena cava that completely blocks circulation in liver. * Patients with dependence on corticosteroids * Patients with active autoimmune diseases requiring systemic immunosuppressive therapy * Patients who are currently receiving or received within past 30 days anti-cancer therapy, local treatments for liver tumors (radiotherapy, embolism, ablation) or liver surgery * Patients currently receiving other investigational treatments (biotherapy, chemotherapy, or radiotherapy) * Patients undergoing current treatment known to interfere with lymphodepleting chemotherapy (cyclophosphamide, etc.). * Participants with other active malignancies (except non-melanoma skin cancer and cervical cancer) within two years. Patients with a history of successfully-treated tumors with no sign of recurrence in the last two years may be enrolled. * Patients with other uncontrolled diseases, such as active infections: * Acute or chronic active hepatitis B or hepatitis C. * HIV-infection * Women who are pregnant